

Recombinant Human IL-21 Protein

Catalog Number: EXRP035



For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.


Product Details

Biological Activity	Measured by a dose-dependent induction of human IFN-gamma secretion by human natural killer lymphoma cells. The ED ₅₀ for this effect is typically <7 ng/mL.
Purity	>98% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining
Endotoxin	<0.01 EU per 1 µg of the protein as determined by the LAL method
Source	Expressed in <i>E. coli</i>
Accession Number	Q9HBE4
Sequence	Gln32-Ser162, with an N-terminal Met MQDRHMIRMRLQLIDIVDQLK NYVNDLVPEF LPAPEDVETN CEWSAFSCFQ KAQLKSANTG NNERIINVSI KKLKRKPPST NAGRRQKHRL TCPSCDSYEK KPPKEFLERF KSLQKMIHQ HLSSRTHGSE DS
Molecular Weight	15.4 kDa (predicted)
Formulation	Lyophilized from sterile PBS with Trehalose, pH 7.4


Storage and Preparation

Shipping	Shipped at ambient temperature.
Stability and Storage	<ul style="list-style-type: none">12 months from date of receipt at -20°C to -70°C, lyophilized powder.3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute at 100 µg/mL in sterile PBS.

Data Images



Recombinant Human IL-21



Human IL-21 Treatment of Human NK Lymphoma Cells Induces Dose-dependent Human IFN-gamma Secretion. Human NK lymphoma cells were seeded at 2×10^5 /mL and treated with increasing concentrations of Recombinant Human IL-21. After 3 days, supernatant was collected, and human IFN-gamma concentration was quantitatively determined using an ELISA. The ED₅₀ for this effect is typically <7 ng/mL.